Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation. by Segovia, Mercedes et al.
1 
 
Targeting TMEM176B enhances antitumor immunity and 
augments the efficacy of immune checkpoint blockers by 
unleashing inflammasome activation 
 
Mercedes Segovia1,2,3,10, Sofia Russo1,2,3,10, Mathias Jeldres1,3, Yamil D. Mahmoud4, 
Valentina Perez1,3, Maite Duhalde1,3, Pierre Charnet5, Matthieu Rousset5, Sabina 
Victoria1,3, Florencia Veigas4, Cédric Louvet6, Bernard Vanhove6,7, R. Andrés Floto8, 
Ignacio Anegon6, Maria C. Cuturi6,12*, M. Romina Girotti4,11, Gabriel A. Rabinovich4,9,11 and 
Marcelo Hill1, 2, 3,11,12*.  
1. Laboratory of Immunoregulation and Inflammation, Institut Pasteur de Montevideo; 
11400, Montevideo, Uruguay.  
2. Immunobiology Department, Faculty of Medicine, University of the Republic; 
11800, Montevideo, Uruguay.  
3. Center for Translational Immunology, FOCIS Center of Excellence, Montevideo 
Faculty of Medicine, Institut Pasteur de Montevideo, 11400 Montevideo, Uruguay.  
4. Laboratory of Immunopathology and Laboratory of Translational Immuno-
Oncology, Institute of Biology and Experimental Medicine (IBYME), National 
Council of Scientific and Technical Investigations (CONICET), C1428 Buenos 
Aires, Argentina.  
5. Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS ENSCM, 
Université de Montpellier. 34093 Montpellier, France. 
6. INSERM UMR 1064, Center for Research in Transplantation and Immunology; 
Université de Nantes; CHU Nantes, Institut de Transplantation Urologie 
Néphrologie (ITUN); 44093 Nantes, France. 
7. OSE Immunotherapeutics. 44200 Nantes, France 
8. Molecular Immunity Unit, Department of Medicine, University of Cambridge.     
CB2 0QH Cambridge, UK.  
9. Department of Biological Chemistry, School of Exact and Natural Sciences, 
University of Buenos Aires, C1428 Buenos Aires, Argentina. 
10. Equal contribution.     
11. Co-senior authors 
12. Lead contact 







Although immune checkpoint blockers have yielded significant clinical benefits in patients 
with different malignancies, the efficacy of these therapies is still limited prompting the 
identification of novel immunotherapeutic targets. Here, we show that disruption 
of Transmembrane Protein 176b (Tmem176b)/Tolerance-Related and Induced cation 
transporter (Torid) contributes to CD8+ T cell-mediated tumor growth inhibition by 
unleashing inflammasome activation. Lack of Tmem176b enhances the antitumor activity 
of anti-CTLA-4 antibodies through mechanisms involving caspase-1/IL-1 activation. 
Accordingly, patients responding to checkpoint blockade therapies display an activated 
inflammasome signature. Finally, we identify BayK8644 as a potent Tmem176b inhibitor 
that promotes CD8+ T cell-mediated tumor control and reinforces the antitumor activity of 
both anti-CTLA-4 and anti-PD-1 antibodies. Thus, pharmacologic de-repression of the 
inflammasome by targeting TMEM176B may enhance the therapeutic efficacy of immune 
checkpoint blockers.  
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SIGNIFICANCE 
Therapies targeting immune checkpoint pathways have revolutionized treatment of 
several cancers. However, innate and adaptive mechanisms may limit the clinical efficacy 
of this immunotherapeutic modality. Here, we identify the Transmembrane Protein 176B 
(Tmem176b) as an innate immune checkpoint that curtails CD8+ T cell mediated immunity 
by repressing inflammasome activation. Genetic disruption or pharmacologic inhibition of 
Tmem176b potentiates antitumor immunity and enhances the efficacy of anti-CTLA-4 and 
anti-PD-1 antibodies in mice by unleashing inflammasome activation. Accordingly, an 
activated inflammasome signature delineates favorable clinical responses in patients 
receiving immune checkpoint blockers. Thus, targeting TMEM176B may influence 







 TMEM176B inhibits the NLRP3 inflammasome by controlling cytosolic Ca++.  
 Lack of Tmem176b enhances antitumor immunity via activation of the caspase 1-
IL-1 pathway.  
 Patients responding to immune checkpoint blockers display an inflammasome-
activated signature.  




















Stimulation of adaptive antitumor responses has revolutionized the therapeutic 
management of a variety of cancers (Baumeister et al., 2016; Sharma and Allison, 2015; 
Topalian et al., 2015, 2016). Immune checkpoint blockers unleash antitumor T-cell 
responses by interrupting co-inhibitory signals that normally hold effector T cells in check. 
Blockade of immune checkpoints, including the cytotoxic T lymphocyte-associated protein 
(CTLA)-4 and the programmed cell death-1 (PD-1)/PD ligand-1 (PD-L1) pathway, have 
increased overall survival and progression-free survival of cancer patients. However, only 
a restricted number of patients show clinical benefits (Syn et al., 2017), suggesting that 
other immune inhibitory mechanisms may limit the efficacy of these treatments. Thus, 
identification of novel targets and biomarkers of response to treatment are necessary to 
develop novel immunotherapeutic drug combinations  (Binnewies et al., 2018; Krieg et al., 
2018; Pitt et al., 2016; Sharma et al., 2017). In this regard, an ionic disbalance within the 
tumor microenvironment has been shown to hinder the efficacy of immunotherapeutic 
strategies. High intratumoral K+ led to T-cell dysfunction by inhibiting voltage and Ca++-
dependent K+ channels expressed in anti-tumoral T lymphocytes (Eil et al., 2016), 
suggesting a role for ionic channels as emerging regulatory checkpoints and therapeutic 
targets to reinforce anti-tumor immunity. 
A number of innate immune players can shape antitumor immunity and influence 
cancer immunotherapeutic strategies by positively or negatively controlling T-cell 
activation, differentiation, expansion and survival  (Berraondo et al., 2016). Recognition of 
immunogenic tumors by innate immune sensors including the Tmem173 (STING) type I 
interferon (IFN)  pathway leads to stimulation of CD8+ T cell-mediated immunity and 
potentiation of CTLA-4- and PD-1-targeted therapies (Corrales et al., 2015; Demaria et al., 
2015; Woo et al., 2014). Moreover, a type-I IFN signature is associated with ipilimumab 
sensitivity in melanoma patients (Chiappinelli et al., 2015). Furthermore, STING controls 




 The inflammasome is a cytosolic multiprotein complex which, once activated, 
cleaves caspase 1 which then processes pro-IL-1 and pro-IL-18 to give the active and 
secreted forms of these pro-inflammatory cytokines (Rathinam and Fitzgerald, 2016). 
Altered levels of cytosolic cations have been shown to control secretion of active IL-1 
through modulation of inflammasome activation (Gong et al., 2018; Muñoz-Planillo et al., 
2013; Murakami et al., 2012). Interestingly, activation of the NLRP3 inflammasome in 
dendritic cells (DCs) following chemotherapy triggers vigorous  CD8+ T cell-mediated 
antitumor responses (Ghiringhelli et al., 2009) and immunogenic chemotherapy sensitizes 
tumors to immune checkpoint blockers (Pfirschke et al., 2016). However, the role of the 
NLRP3 inflammasome in modulating checkpoint blockade therapies has not yet been 
explored. 
 Transmembrane Protein 176B (TMEM176B) / Tolerance-related and induced  
(TORID) has been recently identified as an immunoregulatory cation channel 
(Anandasabapathy et al., 2014; Condamine et al., 2010; Drujont et al., 2016; Louvet et al., 
2005; Segovia et al., 2014). This ubiquitously expressed intracellular protein is composed 
by four transmembrane domains containing an ITIM motif in its C-terminal (Condamine et 
al., 2010; Eon Kuek et al., 2016; Louvet et al., 2005). Tmem176a and its homologous 
Tmem176b are members of the CD20-like MS4A family of proteins (Eon Kuek et al., 
2016; Louvet et al., 2005) and are highly expressed in monocytes, macrophages and 
CD11b+ DCs (Condamine et al., 2010; Louvet et al., 2005).  
 Here we show that Tmem176b inhibits activation of the NLRP3 inflammasome and 
hinders development of antitumor T-cell responses by controlling cytosolic Ca++ 
homeostasis. Lack of Tmem176b promotes heightened T-cell mediated tumor growth 
inhibition and reinforces the antitumor activity of immune checkpoint blockers by activating 
inflammasome-dependent caspase 1/IL-1 pathway on myeloid cells. Accordingly, 
patients responding to immune checkpoint blockers exhibit an activated inflammasome 
signature. Finally, we identify BayK8644, a potent Tmem176b inhibitor, that reinforces the 
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anti-tumor responses unleashed by CTLA-4 or PD-1 blockade. Thus, inflammasome 
disinhibition by targeting TMEM176B may enhance the clinical efficacy of checkpoint 






















Tmem176b/TMEM176B inhibits activation of the NLRP3 inflammasome  
To investigate whether TMEM176B regulates inflammasome activation and antitumor 
immunity through the control of ion homeostasis, we first conducted in vivo experiments 
by injecting ATP in WT or Tmem176b-/- mice (Figure 1A). In this model, neutrophil 
recruitment to the peritoneal cavity relies on caspase-1/11 activation (Schroeder et al., 
2017; Xiang et al., 2013). We observed that Tmem176b-/- mice recruited significantly more 
neutrophils than WT animals. To determine whether increased neutrophil recruitment 
upon ATP injection was dependent on inflammasome activation, we generated 
Tmem176b-/-Caspase1-/- double knockout mice (Figure S1A). Peritoneal neutrophil 
recruitment was almost completely inhibited in Tmem176b-/-Caspase1-/- as compared to 
Tmem176b-/- animals (Figure 1A). ATP-induced neutrophil recruitment in Tmem176b-/- 
mice was also interrupted by injection of a caspase-1 inhibitor (Figure S1B). We then 
stimulated WT and Tmem176b-/- bone marrow-derived DCs (BMDCs) with the well-
established NLRP3 activators ATP and nigericin and determined IL-1 in culture 
supernatants as a readout of inflammasome activation. We observed that for both stimuli, 
Tmem176b-/- BMDCs secreted significantly higher levels of IL-1 than WT DCs in a dose 
and time-dependent manner (Figures 1B-C). Similar findings were observed when we 
stimulated BMDCs with aluminum particles (Figure S1C). Western blot studies confirmed 
that the mature (cleaved) form of IL-1 was more abundant in culture supernatants from 
Tmem176b-/- BMDCs as compared to those obtained from WT cells (Figure 1D). 
Moreover, we observed increased mature caspase-1 in supernatants from Tmem176b-/- 
BMDCs compared to WT cells when stimulated with ATP (Figure 1D). Although lower 
doses (2.5 μM) of nigericin induced expression of mature caspase-1 in culture 
supernatants from Tmem176b-/- but not WT BMDCs (Figure 1D), higher doses of this 
NLRP3 activator (5 μM) induced cleavage of caspase-1 in WT DCs whereas LPS alone 
did not (Figure S1D). In agreement with this observation, flow cytometry studies using the 
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FLICA1 reagent revealed higher caspase-1 activation in Tmem176b-/- BMDCs (Figure 1E). 
These results suggest that increased caspase-1 activation contributes to higher secretion 
of mature IL-1 in Tmem176b-/- BMDCs. To confirm these findings, we then induced 
inflammasome activation in WT and Tmem176b-/- BMDCs in the presence or absence of a 
caspase-1 inhibitor. Remarkably, IL-1 secretion was completely inhibited in WT and 
Tmem176b-/- BMDC when caspase-1 activation was interrupted (Figure 1F). Moreover, IL-
1 secretion was completely abrogated in Tmem176b-/-Caspase1-/- BMDCs (Figure 1G). 
Thus, increased IL-1 secretion observed as a result of Tmem176b-/- deficiency requires 
intact caspase-1 activity. Moreover, Tmem176b-/- BMDCs also secreted higher amounts of 
IL-18 as compared to WT cells in a caspase-1-dependent manner (Figure 1H). We then 
speculated that TMEM176B overexpression may impair IL-1 secretion in cells in which 
the inflammasome was activated. To address this issue, THP-1 differentiated 
macrophages were transfected with TMEM176B/GFP or GFP alone (Figure S1E) and 
then treated with LPS and nigericin. TMEM176B over-expression impaired IL-1 secretion 
as compared to GFP-transfected cells (Figure 1I). This effect was not associated with 
increased cell death as compared to GFP-transfected cells (Figure S1F). Thus, cation 
channel TMEM176B inhibits activation of the NLRP3 inflammasome. 
 
TMEM176B inhibits the inflammasome through the control of cytosolic Ca++ 
TMEM176B is an endophagosomal non-selective monovalent cation channel 
(Segovia et al., 2014). Because the NLRP3 inflammasome is tightly regulated by cytosolic 
K+ (Muñoz-Planillo et al., 2013) and Ca++ (Murakami et al., 2012) levels, we speculated 
that TMEM176B may inhibit inflammasome activation through the regulation of ion 
homeostasis. To address this question, we first determined cytosolic Ca++ levels using the 
ratiometric Ca++-sensitive probe Fura-2 in WT and Tmem176b-/- BMDCs stimulated with 
ATP. BMDCs lacking Tmem176b showed greater cytosolic Ca++ as compared to WT 
BMDCs (Figure 1J). Interestingly, intracellular Ca++ chelation using BAPTA-AM completely 
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blocked IL-1 secretion in WT and Tmem176b-/- BMDCs (Figure 1K). This effect was also 
dependent on K+ efflux in WT and Tmem176b-/- BMDCs (Figure 1L).  
We recently proposed that Ca++-activated K+ channels are involved in ATP-
triggered inflammasome activation (Schroeder et al., 2017). We therefore inhibited Ca++-
activated K+ channels in ATP-treated WT and Tmem176b-/- BMDCs and determined the 
amounts of IL-1 in culture supernatants. Inhibition of channel function using iberiotoxin or 
hydroxychloroquine (Schroeder et al., 2017) led to dose-dependent reduction in IL-1 
secretion by WT BMDCs. Interestingly, IL-1 secretion by Tmem176b-/- BMDCs was 
completely abrogated by both inhibitors at doses that partially inhibited IL-1 secretion in 
WT BMDCs (Figure 1M-N). Thus, heightened inflammasome activation in Tmem176b-/-
BMDCs is highly dependent on Ca++-activated K+ channels. These results suggest that 
TMEM176B impairs ATP-induced cytosolic Ca++ accumulation, preventing Ca++-dependent 
K+ channel-driven inflammasome activation.  
 
Lack of Tmem176b restrains tumor growth in an IL-1- and caspase-1-dependent 
manner 
To investigate whether TMEM176B-mediated regulation of inflammasome 
activation may influence anti-tumor immunity, we first examined the association of 
TMEM176B expression in human cancer. High stromal TMEM176B expression was 
associated with significantly lower overall survival in colon cancer patients (n=90; 
p=0.0194; Log-rank Mantel-Cox test) (Figure S2A-B). Moreover, we detected a striking 
negative correlation between TMEM176B and NLRP3/IL1B expression from single cell 
RNA-seq analysis in macrophages infiltrating human melanoma [data analyzed from 
(Jerby-Arnon et al., 2018)], suggesting a role for this axis in the tumor microenvironment 
(Figure S2C).  Accordingly, Tmem176b-/- mice inoculated with MC38 (colon), LL/2 (LLC1; 
lung) or EG7 (thymic lymphoma) cell lines showed higher survival (Figure 2A) and 
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reduced tumor growth (Figure S2D) compared to WT mice. Although Tmem176b is 
expressed by the three tumor cell lines studied (Figure S2E), immune cells from tumor-
bearing Tmem176b-/- animals did not show enhanced in vivo cytotoxicity against WT cells 
as compared to tumor-bearing Tmem176b+/+ mice (Figure S2F), suggesting that tumor-
associated Tmem176b is not immunogenic in Tmem176b-/- hosts.  
 To investigate the mechanisms underlying TMEM176B contribution to tumor 
growth, we then studied inflammasome activation in tumors developed in WT and 
Tmem176b-/- mice. We found no differences in caspase-1 activation when comparing 
those tumors lysates (Figure S2G). However, we did find increased caspase-1 activation 
in tumor-draining lymph nodes (TDLN) from Tmem176b-/- mice as compared to WT 
animals as shown by Western blot (Figure 2B-C) and immunofluorescence staining 
(Figure 2D-E). Moreover, flow cytometry analysis revealed augmented caspase-1 
activation in resident CD11chi MHCII+ CD11b+ classical DCs (cDCs) in Tmem176b-/- versus 
WT TDLN from tumor-bearing mice (Figure 2F-G and Figure S2H). Migratory and resident 
DCs were discriminated based on CD11c and MHCII expression (Figure S2H) as 
described (Kissenpfennig et al., 2005; Laoui et al., 2016). Interestingly, CD11chi MHCII+ 
CD11b+ cDCs expressed considerable amounts of Tmem176b (Crozat et al., 2011) and 
TDLN contained high numbers of CD11b+ Tmem176b+ cells compared to lymph nodes 
from naïve animals (Figure S2I).  
 Since CD11b+ cDCs induce differentiation of Th17 cells (Durai and Murphy, 2016), 
we then speculated that this CD4+ T-cell subset may augment in TDLN from Tmem176b-/- 
mice. We observed increased frequency of TCR+ CD4+ RORt+ cells in TDLN 
from Tmem176b-/- animals as compared to WT and anti-IL-1β-treated Tmem176b-/- mice 
(Figure S2J). Moreover, in vitro re-stimulation of TDLN cells with OVA showed increased 
proportion of IL-17+ CD4+ T cells in Tmem176b-/- as compared to WT mice (Figure S2K) 
and in vivo IL-17A blockade showed a clear trend toward suppression of the antitumor 
effect in tumor-bearing Tmem176b-/- mice (Figure S2L). Thus, Tmem176b deficiency is 
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associated with an enhanced frequency of functional TCR+ CD4+ RORt+ IL-17+ T cells in 
an inflammasome-dependent manner.  
 To study whether increased inflammasome activation could be responsible of 
tumor control in mice lacking Tmem176b, we blocked IL-1 and studied EG7 tumor 
development. Whereas Tmem176b-/- mice showed reduced tumor growth and increased 
mice survival when treated with control IgG, this effect was eliminated when mice were 
treated with anti-IL-1 neutralizing antibodies (Figure 2H). Thus, Tmem176b deletion 
inhibits development of syngeneic tumors in an IL-1-dependent fashion. Tumor growth 
control was also rescued in Tmem176b-/-Caspase1-/- double knockout mice (Figure 2I), 
suggesting that the diminished tumor growth observed in Tmem176b-/- mice was 
dependent on inflammasome activation  
 To further examine the cellular effectors involved in tumor growth inhibition in 
Tmem176b-/- mice, we then analyzed a panel of immunological mediators by quantitative 
RT-PCR. Notably, no differences were found between tumors grown in WT or Tmem176b-
/- mice (Figure S3A left panel). Moreover, we did not find significant changes in the 
percentage or absolute numbers of infiltrating myeloid, B, NK, NKT or CD4+ T cells 
between WT and Tmem176b-/- tumors (Figure S3B). However, the percentage of total 
CD8+ TCR+ cells within the tumor infiltrate as well as the absolute number of total and 
tumor-specific CD8+ T cells were considerably increased in tumors grown in Tmem176b-/- 
mice compared to those developed in WT mice (Figure S4A-B). Notably, although 
increased absolute numbers of CD4+ CD25+ Foxp3+ regulatory T (Treg) cells were found 
within tumors developed in Tmem176b-/- as compared to WT animals (Figure S4C), an 
increased Teff (CD8) / Treg (Foxp3) ratio was apparent (Figure S4C). Moreover, tumor-
infiltrating CD8+ T cells from Tmem176b-/- mice showed greater proliferation compared to 
those obtained from WT animals when re-stimulated in vitro with OVA MHC-I peptide 
(Figure S4D). Interestingly, we found downregulation of the Treg-related molecules 
Foxp3, CTLA-4, CCL5, CCL19 and CCL22 in TDLN from Tmem176b-/- versus WT mice 
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(Figure S3A right panel). Moreover, decreased percentages but not absolute numbers of 
TCR+ CD4+ Foxp3+ Treg cells were observed in TDLN from Tmem176b-/- versus WT mice 
(Figure S5A-B). Moreover, the CD8/Treg ratio in TDLN was significantly increased in mice 
lacking Tmem176b (Figure S5B). In vivo, MHC I-dependent CD8+ T-cell mediated 
cytotoxicity against the tumor-associated OVA antigen was increased in tumor-bearing 
Tmem176b-/- compared to WT mice (Figure 2J and Figure S4E). This effect was prevented 
in Tmem176b-/- animals treated with anti-IL-1 antibodies (Figure 2K) as well as in 
Tmem176b-/-Caspase-1-/- animals (Figure 2L). Within the tumor microenvironment, CTLs 
from Tmem176b-/-Caspase-1-/- showed lower expression of the degranulation marker 
CD107a as compared to Tmem176b-/- mice (Figure S4F). Interestingly, depletion of CTLs 
in Tmem176b-/- mice using an anti-CD8 monoclonal antibody rescued tumor growth to 
similar levels as those observed in WT mice (Figure 2M). Thus, Tmem176b deletion 
enhances CTL-mediated-tumor control through mechanisms involving the caspase-1-IL-
1 pathway. This mechanism is associated with inflammasome-dependent induction of 
TCR+ CD4+ RORt+ cells. Altogether, these results support a role for TMEM176B as an 
emerging immune checkpoint that interrupts inflammasome activation and links innate and 
adaptive antitumor responses. 
 
Inflammasome activation reinforces immune checkpoint blockade therapies 
Given the influence of Tmem176b deletion in antitumor immunity, we investigated 
whether targeting this ion channel might control the efficacy of checkpoint blockade 
therapies. Remarkably, we found greatly diminished tumor growth when anti-CTLA-4 
antibodies were inoculated in Tmem176b-/- as compared to WT mice. Improved survival 
observed in anti-CTLA-4-treated Tmem176b-/- mice was dependent on inflammasome 
activation as this effect was abrogated in Tmem176b-/-Caspase1-/- animals (Figure 3A). To 
investigate this further, we injected anti-CTLA-4 or anti-PD-1 mAb in EG7 tumor-bearing 
Caspase 1/11-/- or Nlrp3-/- mice. Genetic deficiency of Caspase 1/11 eliminated the anti-
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tumor effects triggered by CTLA-4 or PD-1 blockade (Figure 3B). Although the 
experiments performed in Nlrp3-/- mice did not reach statistical significance, there was a 
clear tendency towards lower survival in those mice when treated with anti-CTLA-4 or 
anti-PD-1 mAb (Figure 3C). Moreover, we found no differences in tumor growth in mice 
lacking inflammasome components under control conditions (Figure 3B-C) in agreement 
with previous reports (Ghiringhelli et al., 2009). These results highlight the importance of 




Sensitivity to immune checkpoint blockers is associated with an 'inflammasome 
activated' signature in cancer patients  
To further understand the clinical relevance of our findings, we then investigated 
whether inflammasome-related genes might be associated with clinical responses in 
patients treated with immune checkpoint blockers. We first analyzed data obtained from 
whole-exome sequencing and transcriptomics of a published cohort of melanoma patients 
treated with checkpoint inhibitors (Riaz et al., 2017). These studies focused on 
pretreatment and on treatment tumor biopsies from patients that progressed to anti-CTLA-
4 therapy and were further treated with anti-PD-1 antibodies (IPI-progressing) and 
patients treated with anti-PD-1 antibodies who had not received anti-CTLA-4 antibodies 
(IPI-naïve). Strikingly, in the IPI-naïve population of non-responder patients, only two 
inflammasome-related genes were significantly up-regulated during treatment as 
compared to the pre-treatment stage. These genes were TMEM176A and TMEM176B 
(Figure 4A and Table S1). These observations emphasize the role of TMEM176 ionic 
channels as potential mediators of resistance to checkpoint blockade therapies.  
Interestingly, when comparing patients responding or not to anti-PD-1 at the pre-
treatment stage, we found no significant differences in inflammasome-related genes either 
in the bulk population (Table S2), IPI-naïve (Table S3) or IPI-progressed (Table S4) 
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groups. However, 8 inflammasome-related genes were significantly up-regulated in 
responders versus non-responder patients in the bulk population during anti-PD-1 
treatment (Figure 4B). TMEM176A and TMEM176B were two of the inflammasome-
related genes that were significantly upregulated in patients responding to anti-PD-1, 
suggesting that they could function as a counter-regulatory mechanism in response to 
treatment. Similar findings were observed in the IPI-naïve population (Table S5). We then 
performed a paired analysis comparing pre-treatment and on anti-PD-1 treatment tumor 
biopsies from responder patients. In this case, we found 11 inflammasome-related genes 
that were significantly up-regulated during anti-PD-1 therapy as compared to the pre-
treatment biopsies (Figure 4C). Similar results were found when analyzing the IPI-naïve 
population (Table S6).  
We then analyzed transcriptomic datasets from patient biopsies to estimate the 
diversity of leukocyte populations infiltrating tumors using the CIBERSORT method 
(Newman et al., 2015). We observed increased relative frequencies of CD8+ T cells and 
activated memory CD4+ T cells during anti-PD-1 treatment versus the pre-treatment stage 
in responders but not in progressor patients (Figure 4D). Absolute total number of 
leukocytes, CD8+ T cells and activated memory CD4+ T cells were also increased (Figure 
4E). In patients responding to anti PD-1 therapy, the total number of leukocytes as well as 
the frequency of CD8+ T cells and activated memory CD4+ T cells were positively 
associated with the expression of NLRP3 during ongoing treatment (Figure 4F). These 
observations reinforce the concept that inflammasome activation controls T-cell immunity 
in patients treated with immune checkpoint blockers.  
To validate further these observations, we analyzed the inflammasome gene 
expression profile in longitudinal tumor biopsies from melanoma patients treated 
sequentially with anti-CTLA-4 and anti-PD-1 antibodies (Chen et al., 2016). These authors 
studied gene expression profiling (GEP) via a custom 795-gene NanoString panel 
composed of immune and cancer-related genes. Of note, TMEM176A and TMEM176B 
were not included in the NanoString panel used by Chen et al. The authors found no 
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significant differences in GEP when comparing responders versus progressors at baseline 
(before CTLA-4 or PD-1 blockade) or following anti-CTLA-4 or anti-PD-1 therapy. 
Consistently, we found no significant expression of inflammasome-related genes at these 
stages (Figures S6A-B and S7A-B). These results are in agreement with our findings from 
the analysis from the Riaz et al cohort at the pre-treatment stage (Tables S1-4). However, 
the authors found 411 genes that were significantly regulated (mostly up-regulated) in 
responding versus progressing patients following early PD-1 blockade. In those patients, 
15/16 inflammasome-related genes were significantly upregulated in responders 
compared to progressors (Figure 5A). We then performed a paired analysis of the 16 
inflammasome-related genes in biopsies of 5 responding patients and 7 progressors 
comparing gene expression prior and during anti-PD-1 therapy. All these patients had 
progressed to anti-CTLA-4 therapy. Critically, 5/5 patients responding to anti-PD-1 
showed a significant up-regulation of inflammasome-related genes during anti-PD-1 
treatment (Figure 5B). Moreover, 4/7 patients who did not respond to anti-PD-1 therapy 
significantly downregulated the inflammasome signature during PD-1 blockade (Figure 
5B). Thus, gene expression profiles from biopsies of two independent cohorts of 
melanoma patients treated with immune checkpoint blockers revealed strong association 
between inflammasome activation and clinical responses. These findings support the 
notion that inflammasome activation contributes to antitumor responses triggered by 
immune checkpoint blockers and highlights the potential role of an 'inflammasome 
activation' signature as a biomarker of response to immune checkpoint blockade. 
   
Pharmacologic inhibition of Tmem176b triggers inflammasome-dependent tumor 
control and improves the efficacy of immune checkpoint blockers 
The up-regulation of inflammasome-related genes in patients responding to 
immune checkpoint blockers (Figures 4 and 5), the contribution of caspase 1/11 to the 
success of anti-CTLA-4 and anti-PD-1 therapies (Figure 3) and the central role of 
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TMEM176B as a potent inflammasome inhibitor (Figure 1), suggested the possibility of 
targeting this pathway to improve the efficacy of immune checkpoint blockers. To identify 
drugs capable of inhibiting Tmem176b-dependent ion flux and triggering inflammasome 
activation, we set up an in vitro assay. Briefly, CHO-7 cells were transfected with 
Tmem176b and Tmem176a-mCherry. Cells were then loaded with the Na+-sensitive 
fluorescent dye Asante NaTRIUM Green 2 (ANG-2). We observed increased ANG-2 MFI 
in mCherry+ compared to mCherry- cells. We then screened a compound library known to 
modulate ion channels activity (Supplementary Dataset 1). We found that both 
enantiomers (+) and (-) of BayK8644 potently inhibited Tmem176b-a-dependent Na+ 
influx, while minimally affecting Tmem176b-a negative cells (Figure 6A-B and Figure 
S8A). Therefore, we decided to focus on these compounds also because they are 
members of the dihydropyridin family, which are drugs currently used in clinical settings. 
Whereas (+) BayK8644 is known to inhibit L-type voltage-dependent Ca++ channels, the (-) 
stereoisomer activates those channels (Grove et al., 1991; Hamilton et al., 1987; Yatani et 
al., 1988). Since both isomers inhibit Tmem176b/a activity, it is unlikely that our 
observations could be explained by indirect effects on Na+ influx through the modulation of 
Ca++ channels. Although we cannot rule out the possibility that BayK8644 could inhibit 
Tmem176a in the ANG-2 experiments, in electrophysiology studies using Tmem176b-
overexpressing Xenopus oocytes, (+) BayK8644 completely inhibited Tmem176b-
dependent current (Figure 6B). Therefore, we focused on the (+) isomer for functional 
experiments.  
Because BayK8644 inhibits Tmem176b-dependent ion fluxes, we asked whether 
this drug could trigger inflammasome activation in BMDCs. We observed that BayK8644 
induced IL-1 secretion and caspase-1 activation in LPS-primed WT BMDCs but not in 
Tmem176b-/- cells (Figure 6C and Figure S8B-D). Furthermore, BayK8644-induced IL-1 
was inhibited by the KCa inhibitors TEA and HCQ (Figure 6D). Thus, BayK8644 treatment 
on WT BMDCs phenocopied Tmem176b-/- cells as IL-1 secretion was highly dependent 
on Ca++-activated K+ channels. In THP-1 macrophages, TMEM176B-dependent inhibition 
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of IL-1 secretion was prevented when these cells were treated with BayK8644 (Figure 
6E). These results indicate that BayK8644 triggers inflammasome activation through 
inhibition of TMEM176B.  
To evaluate the pre-clinical relevance of these findings, we then explored whether 
BayK8644 treatment may inhibit tumor growth. Administration of BayK8644 (i.p) 
significantly increased survival of tumor-bearing WT but not Tmem176b-/- mice (Figure 6F) 
compared to injection of vehicle control, highlighting the ability of the drug to restrain 
tumor growth through inhibition of Tmem176b. Of note, in vitro treatment of EG7 thymic 
lymphoma cells with BayK8644 did not induce apoptosis at similar doses as those 
detected in plasma after i.p injection (Figure S8E). To explore whether BayK8644 
recapitulated the effects in tumor growth control observed in untreated Tmem176b-/- mice, 
we evaluated the effects of the drug in inflammasome activation by disrupting important 
components of this pathway. We found that BayK8644 significantly improved survival of 
WT but not Caspase 1/11-/- tumor-bearing mice (Figure 6G). Consistent with this 
observation, BayK8644 increased the frequency of CD11b+ cDCs expressing active 
caspase-1 in TDLN (Figure 6H). 
Similar to Tmem176b-/- mice, which controlled tumor growth via IL-1- and CD8+ T 
cell-dependent mechanisms, we observed that BayK8644 increased CD8+ T cell-mediated 
tumor cytotoxicity in vivo (Figure 6I). Moreover, BayK8644-induced tumor control was 
dependent on CD8+ T cells, since depletion of these cells completely abolished the 
antitumor effect of this inhibitor (Figure 6J and Figure S8F). Thus, BayK8644 restrains 
tumor growth in a Tmem176b-, caspase-1/11- and CD8+ T cell-dependent manner in EG7 
tumors. Moreover, BayK8644 significantly impaired growth of CT26 colon cancer cells in 
BALB/c mice (Figure S8G-H). Thus, BayK8644 emerges as a new immunotherapeutic 
agent that limits tumor growth by licensing inflammasome activation.  
 Finally, we evaluated whether BayK8644 administration may enhance the 
antitumor activity of immune checkpoint blockers. Compared with mice treated with 
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monotherapy, administration of BayK8644 in combination with anti-CTLA-4 antibodies 
significantly improved survival of tumor (EG7)-bearing mice (Figure 6K). Moreover, 
therapeutic administration of BayK8644 in mice with EG7 established tumors significantly 
improved the anti-tumoral effect of anti-PD-1 treatment (Figure 6L), whereas BayK8644 
monotherapy was not effective in this therapeutic protocol (data not shown). Interestingly, 
combination of anti-PD-1 with BayK8644 was associated with an increased absolute 
number and percentage of TCRβ+CD4+RORγt+ T cells in TDLN (Figure S8I) and 
increased frequency of tumor-specific CD8+ T cells within the tumor microenvironment 
(Figure 6M) as compared to anti-PD-1 monotherapy. Depletion of CD8+ T cells in anti-PD-
1 + BayK8644-treated animals abrogated antitumor immunity (Figure 6N). This 
observation might be explained by concomitant CTL-mediated mechanisms required for 
both the antitumor activity of BayK8644 (Figure 6J and S8F) and anti-PD-1 therapy 
(Sharma and Allison, 2015). Thus, as expected, combination treatment strongly relies on 
the CD8+ T-cell compartment. Furthermore, BayK8644 significantly enhanced the anti-
tumoral effect of anti-PD-1 therapy in mice bearing 5555 melanoma (Figure 6O), whereas 
this effect was also apparent in LL/2 lung cancer (Figure S8J-K) and MC38 colon cancer 
(Figure S8L-M) models, although not reaching statistical significance. Thus, unleashing 
inflammasome activation by targeting Tmem176b improves the anti-tumor activity of 
checkpoint inhibitors in different tumor models. Moreover, whereas BayK8644 reinforced 
the anti-tumor effects of anti-PD-1 treatment in mouse melanoma, it did not enhance 
tumor growth inhibition induced by anti-CTLA-4 and anti-PD-1 combination therapy, at 
least in this model (Figure S8O). Given the pharmacologic impact of channel inhibitors in 
cardiomyocyte function, we finally examined whether dihydropyridin BayK8644 may lead 
to acute cardiac toxicity. Notably, Bayk8644 treatment was not associated with 
electrocardiographic nor echocardiographic alterations 30 min after i.v. injection compared 
to mice treated with vehicle control (Tables 1-2). Thus, pharmacological inhibition of 
TMEM176B by Bayk8644, represents a novel therapeutic approach to unleash 
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inflammasome activation, leading to potentiation of CD8+ T-cell-dependent antitumor 























In this study, we demonstrate a central role of the inflammasome as a novel target 
to reinforce CD8+ T cell-dependent antitumor immunity and enhance the efficacy of 
immune checkpoint blockade therapies. In particular, we demonstrate the key role of 
TMEM176B, an ionic channel expressed on myeloid cells (including cDCs) as a negative 
regulator of inflammasome activation. Furthermore, we identify BayK8644 as a potent 
TMEM176B inhibitor that reinforces antitumor immunity and enhances the efficacy of 
immune checkpoint blockers via inflammasome activation. Finally, we highlight the 
predictive value of NLRP3 inflammasome activation in clinical responses to immune 
checkpoint blockade in two independent cohorts. Thus, patients who do not respond to 
immune checkpoint blockers are expected to benefit from therapeutic strategies capable 
of triggering inflammasome activation.  
Most immunotherapeutic approaches have focused on drugs targeting adaptive 
components of the immune system. However, innate immune pathways have recently 
emerged as potential targets amenable of intervention to trigger and control downstream 
adaptive players. In this regard, stimulation of STING activity has been shown to enhance 
the anti-tumoral effect of checkpoint blockers (Corrales et al., 2015; Demaria et al., 2015; 
Woo et al., 2014). Importantly, a type-I IFN pathway signature correlates with sensitivity to 
anti-CTLA-4 antibodies in melanoma patients (Chiappinelli et al., 2015). Nevertheless, the 
role of the IL-1/IL-18/inflammasome in modulating anti-tumor responses is still 
controversial (Karki et al., 2017; Apte and Voronov, 2008). It has been proposed that the 
cell type in which inflammasome is activated and the nature of acute versus chronic 
inflammasome activation may dictate the outcome of the antitumor responses (Karki et al., 
2017).   
 Immunogenic cell death triggered by chemotherapeutics, which sensitizes tumors 
to checkpoint blockade therapies, relies in NLRP3 inflammasome activation by DCs 
(Ghiringhelli et al., 2009; Pfirschke et al., 2016). Although recently proposed to play a role 
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in the outcome of immunotherapeutic approaches (Mangan et al., 2018), the direct 
contribution of the inflammasome to adaptive checkpoint blockade remains elusive. Here 
we identified a new strategy to reinforce antitumor responses by targeting TMEM176B 
and promoting inflammasome disinhibition. Our results suggest that inflammasome 
activation plays a central role in antitumor immunity triggered by anti-CTLA-4 and anti-PD-
1 antibodies. It is worth noting that experiments using Nlrp3-/- animals did not reach 
statistical significance, whereas experiments in animals lacking downstream effectors 
Caspase-1/11 did. These observations suggest that different inflammasomes may be 
involved in the anti-tumoral effect triggered by anti-CTLA-4 and anti-PD-1 therapies. 
Accordingly, analysis of anti-PD-1-treated melanoma patients (Figures 4 and 5) suggest 
that NLRP6, NLRP7, AIM2 and NLRC4 inflammasomes might contribute to antitumor 
responses unleashed by checkpoint blockers. Although the requirement of caspase-1 
autoproteolysis can differ within different inflammasomes (Broz et al., 2010) and caspase-
1 may cleave other proteins than IL-1β and IL-18 (Sokolovska et al., 2013), to our 
knowledge, caspase-1 and caspase-11 activation mostly depend on inflammasomes. 
Thus, it is unlikely that results obtained with both Caspase-1/11-/- and Tmem176b-/-
Caspase-1-/- mice might rely on inflammasome-independent mechanisms. 
 Our results suggest that TMEM176B might be a predictive marker of response to 
anti-PD-1 therapy. In addition, TMEM176B expression in the tumor stroma was 
associated with poor survival in colorectal cancer patients suggesting a potential role of 
this ion channel as a prognostic factor. Interestingly, TMEM176B was associated with 
diminished NLRP3 and IL1B expression in macrophages infiltrating human melanoma, 
suggesting that this ion channel may function as an innate checkpoint signal that hinders 
immune responses in the tumor microenvironment. However, our results in experimental 
models support a key role for Tmem176b in the modulation of inflammasome activation 
mostly in TDLN during the induction phase of anti-tumor responses. Thus, Tmem176b-
dependent immune inhibitory mechanisms may operate within the tumor 
microenvironment and TDLN. Although further mechanistic studies are warranted to 
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elucidate the molecular pathways that control Tmem176b expression, we found a 
reciprocal regulation of this ion channel by inflammasome activation (Figure S9A). 
Notably, LPS+ATP treatment induced a striking up-regulation of IL-6 and TNF-α (Figure 
S9A) and a very modest increase in cell death (Figure S9B) as compared to untreated 
BMDCs, excluding the possibility that down-regulation of Tmem176b by inflammasome 
activation could be related to massive induction of cell death. 
Recently, it has been proposed that pharmacologic manipulation of ion channels 
may influence NLRP3 inflammasome activation (Gong et al., 2018). Here we show that 
BayK8644 attenuates tumor growth by inhibiting TMEM176B activity, leading to 
inflammasome disinhibition and CD8+ T cell responses with no evident signs of 
cardiotoxicity. Remarkably, BayK8644 treatment recapitulated Tmem176b deficiency as 
shown by increased caspase-1 activation in CD11b+ cDCs in TDLN. These observations 
are in line with the high expression of TMEM176B in these cells (Anandasabapathy et al., 
2014; Crozat et al., 2011).  
 Remarkably, in this study we showed that Tmem176b deficiency is associated with 
increased inflammasome activation both in vitro and in vivo. Moreover, TMEM176B 
overexpression inhibited LPS and nigericin-induced IL-1 secretion by macrophages. 
Increased inflammasome activation in Tmem176b-/- DCs was dependent on K+ efflux and 
increased cytosolic Ca++. In this regard, the hierarchy between Ca++ and K++ in 
inflammasome activation is a matter of debate (Gong et al., 2018). We have previously 
shown that Ca++-activated K+ channels such as KCa1.1 can mediate NLRP3 
inflammasome activation and are inhibited by hydroxychloroquine (Schroeder et al, 2017). 
Here we found complete inhibition of IL-1 secretion in Tmem176b-/- DCs by the specific 
KCa1.1 inhibitor iberiotoxin as well as by hydroxychloroquine. Secretion of IL-1 by 
Tmem176b-/- DCs seems therefore to be highly dependent on KCa1.1 channels. In this 
sense, sustained K+ efflux in T cells through the voltage-gated (Kv1.3) or Ca++-activated 
(KCa3.1) K+ channels has been shown to reinvigorate tumor-infiltrating T cells (Eil et al., 
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2016). Our results suggest that K+ efflux in DCs may also promote anti-tumor immunity by 
triggering inflammasome activation, a process that is repressed by TMEM176B. Taken 
together, these observations highlight a regulatory role for ion homeostasis in controlling 
anti-tumor immunity through modulation of both innate and adaptive immune programs.  
 In conclusion, our study links inflammasome activation to antitumor responses 
triggered by immune checkpoint blockers, highlighting a central role for TMEM176B, an 
ion channel expressed on myeloid cells, in repression of T-cell dependent immunity. 
Further efforts should be aimed at evaluating the clinical efficacy and safety of 
inflammasome disinhibition in the treatment of cancer patients, particularly those resistant 
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Figure 1. The ionic channel Tmem176b/TMEM176B inhibits the NLRP3 
inflammasome 
A) Six-to-eight weeks-old male WT, Tmem176b-/- and Tmem176b-/-Caspase1-/- mice 
were injected i.p with vehicle control (PBS) or 20 mg/kg ATP. Four h later, peritoneal 
lavage was performed and absolute numbers of neutrophils (CD11b+ Ly6Cint Ly6G+) were 
determined by flow cytometry. The left panel shows representative dot plots and the right 
panel shows quantifications for the different groups. In the plots, CD11b+ cells were 
analyzed for Ly6C and Ly6G expression. At least six animals were studied in each group 
in two independent experiments. ns: not significant; * p<0.05; One-way ANOVA test.  
B-C) WT and Tmem176b-/- bone marrow-derived DCs (BMDCs) were treated with LPS 
(0.25 µg/ml) for 4 h, then washed and treated with the indicated doses of ATP or 
nigericine (Nig) for the indicated times. Dose-response experiments are shown in B) 
whereas time-response experiments are depicted in C). Culture supernatants were 
harvested and IL-1 was determined by ELISA. One experiment representative of five is 
shown.  * p<0.05; ** p<0.01; Two-way ANOVA test.  
D) Western blot analysis of pro-IL-1 and pro-caspase-1 (lysates) or IL-1 and 
caspase-1 (supernatants) in WT and Tmem176b-/- BMDCs stimulated with LPS as in B-C) 
and then treated for 90 min with 2.5 µM nigericin or 0.5 mM ATP. Culture supernatants 
and cell lysates were analyzed. One experiment representative of three is shown.  
E) WT and Tmem176b-/- BMDCs were treated with LPS and then with 0.5 mM ATP or 
2.5 µM nigericin (Nig) for 45 min. Cells were harvested and stained with FLICA1 660 to 
determine active caspase-1. One experiment representative of three is shown. * p<0.05; 
Two-way ANOVA test. 
F) IL-1 secretion by WT and Tmem176b-/- BMDCs treated as in E) and compared to 
an experimental condition where caspase-1 was inhibited by adding 10 µM Z-WEHD-FMK 
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15 min before ATP. One experiment representative of three is shown. ** p<0.01; **** 
p<0.0001; Two-way ANOVA test. 
G-H) WT, Tmem176b-/- and Tmem176b-/-Caspase1-/- BMDCs were treated as in E). IL-1 
(G) or IL-18 (H) were determined in culture supernatants by ELISA. One experiment 
representative of two is shown. ND: Not detected. * p<0.05; ** p<0.01; **** p<0.0001; 
Two-way ANOVA test. 
I) THP-1 cells were differentiated to macrophages by treatment with 0.1 µM PMA for 
a 48 h-period. Cells were then electroporated with GFP or GFP-TMEM176B encoding 
pcDNA1.3 plasmids. Sixteen hours later, cells were left untreated or treated for 3 h with 
0.25 µg/ml LPS and then for 2 h with 2.5 µM nigericin (Nig). IL-1 was determined in 
culture supernatants by ELISA. One experiment representative of four is shown. ** 
p<0.01; *** p<0.001; Two-way ANOVA test. 
J) WT and Tmem176b-/- BMDCs were treated for 3 h with 0.25 µg/ml LPS. Cells were 
then loaded with the Ca++-sensitive probe Fura-2. Emission at 340/380 nm was recorded 
in time-laps experiments. 0.5 mM ATP was added when indicated by the arrow.  
K) NLRP3 inflammasome was activated in BMDCs as described in E) but in the 
presence of the intracellular Ca++ chelator BAPTA (100 µM) or DMSO vehicle control. One 
experiment representative of three is shown. *p<0.05. Two-way ANOVA test.  
L) IL-1 determination in BMDSCs following inflammasome activation in the presence 
of control buffer (5 mM) or high K+ buffer (120 mM). One experiment representative of 
three is shown. * p<0.05; Two-way ANOVA test. 
M-N) IL-1 determination in BMDSCs following inflammasome activation in the presence 
or absence of the Ca++-activated K+ channels iberiotoxin (IbTx, in M) or 
hydroxychloroquine (HCQ, in N). One experiment representative of three is shown in each 
case. * p<0.05; ** p<0.01; Two-way ANOVA test. 
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See also Figure S1.  
 
Figure 2. Mice lacking Tmem176b control tumor growth through an IL-1 and 
caspase-1-dependent manner 
A) MC38 colon cancer cells (1 x 106), LL2 lung cancer cells (1 x 105) or EG7 thymic 
lymphoma cells (1 x 106) were s.c. injected in WT and Tmem176b-/- mice. Tumor growth 
and mice survival were monitored every three days. Tumors were measured by its longer 
and shorter diameters. Mice were sacrificed when one of the diameters reached 2 cm. 
The ratio shows the number of surviving animals/ total injected mice from three 
experiments. * p<0.05; ** p<0.01; Log-rank (Mantel-Cox) test.  
B) Western blot analysis of caspase-1 expression and cleavage in tumor-draining 
lymph nodes (TDLN) from WT and Tmem176b-/- mice.  
C) Densitometric analysis of Western blots shown in B. At least 4 animals/group are 
shown. * p<0.05; Student’s t test. 
D) Confocal microscopy of activated caspase-1 expression using the FLICA1 
fluorescent probe in TDLN.  
E) Semiquantification of staining depicted in D is shown. WT and Tmem176b-/- 
animals (n=3 each group) were studied. * p<0.05; *** p<0.001; One-way ANOVA test. 
F) Flow cytometry analysis of FLICA1+ cells within TDLN. SSC: Side Scatter. One 
experiment representative of two is shown.  
G) Evaluation of FLICA1+ CD11b+ and CD11b- classical DCs (cDCs) in the TDLN is 
shown. ns = not significant, *** p<0.001; Student’s t test. 
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H) Survival of Tmem176b-/- EG7 tumor-bearing mice treated with anti-IL-1 or IgG 
control antibodies. The ratio shows the number of surviving animals/ total injected mice 
from one experiment. * p<0.05; Log-rank (Mantel-Cox) test. 
I) Survival of untreated Tmem176b-/- and Tmem176b-/-Caspase1-/- EG7 tumor-
bearing mice. The ratio shows the number of surviving animals/ total injected mice pooled 
from three independent experiments. * p<0.05; Log-rank (Mantel-Cox) test. 
J) In vivo cytotoxicity assay against OVA peptide-pulsed EG7 cells as a model tumor 
antigen. Naïve splenocytes were loaded with high dose DDAO and SIINFEKL peptide. 
Cells were mixed (1:1 ratio) with naïve splenocytes exposed to low dose DDAO without 
peptide. The mix was injected i.v. into naïve and tumor-bearing mice and 4 h later the ratio 
between the high and low DDAO populations in the spleen was determined by flow 
cytometry. Representative histograms are shown in Figure S4E. Data from four different 
animals of one experiment in each group are shown. ** p<0.01; Student’s t test.  
K) In vivo cytotoxicity assay as described in J) in Tmem176b-/- mice previously treated 
with anti-IL-1 or control IgG antibodies. * p<0.05; Student’s t test. 
L) In vivo cytotoxicity assay as described in J) comparing CTLs from tumor-bearing 
Tmem176b-/- and Tmem176b-/-Caspase1-/- mice. Data from two experiments are shown. * 
p<0.05; Student’s t test. 
M) Survival of tumor-bearing WT and Tmem176b-/- mice left untreated or treated with 
anti-CD8 depleting antibodies. The ratio depicts the number of surviving animals/ total 
injected mice. Data from one experiment are shown. * p<0.05; Log-rank (Mantel-Cox) test. 
The genetic background of the animals used was C57BL/6. 





Figure 3. Inflammasome activation reinforces immune checkpoint blockade  
Survival analysis of the indicated groups of animals in response to different treatments. 
The ratio depicts the number of surviving animals/total injected mice.  
A) Tumor (EG7)-bearing WT, Tmem176b-/- and Tmem176b-/-Caspase1-/- mice were 
injected with anti-CTLA-4 or control IgG antibodies and mice survival was studied. 
*p<0.05; Log-rank (Mantel-Cox) test. 
B)  Tumor (EG7)-bearing WT and Caspase1/11-/- mice were injected with anti-CTLA-
4, anti-PD-1 or control IgG antibodies and mice survival was studied. *p<0.05; Log-rank 
(Mantel-Cox) test.  
C) Tumor (EG7)-bearing WT and Nlrp3-/- mice were injected with anti-CTLA-4, anti-
PD-1 or control IgG antibodies and mice survival was studied. Log-rank (Mantel-Cox) test. 
Data from 3 (A-B) or 2 (C) experiments are shown.  
The genetic background of the animals used was C57BL/6. 
 
Figure 4. Analysis of the inflammasome signature in tumor biopsies from 
melanoma patients treated with immune checkpoint blockers (cohort by Riaz et al. 
2017) 
A) Paired analysis of patients who did not respond to anti-PD-1 therapy and were not 
treated previously with anti-CTLA-4 antibody (IPI-naïve) comparing pre-treatment vs on-
treatment melanoma biopsies. TMEM176A and TMEM176B were the only inflammasome-
related genes that were significantly up-regulated in the on-treatment as compared to pre-
treatment population. * p<0.05; Paired Student’s t test.  
See also Table S1.  
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B) Heat maps of transcriptomic analysis from tumor biopsies of melanoma patients 
responding (responders) or not (non responders) to anti-PD-1 therapy. The indicated 
inflammasome-related genes were significantly up-regulated in responder patients 
*p<0.05; unpaired Student’s t test.  
C) Paired analysis of patients responding to anti-PD-1 therapy comparing pre-
treatment vs on-treatment melanoma biopsies. The indicated inflammasome-related 
genes were significantly up-regulated during therapy. p<0.05; Paired Student’s t test.  
D-E) Paired study of pre-treatment vs on-treatment tumor biopsies from bulk patients 
responding to anti-PD-1 therapy analyzed through the CIBERSORT method. The relative 
frequency of CD8+ T cells, activated and non-activated memory CD4+ T cells (D) as well 
as the absolute number of total leukocytes, CD8+ T cells and activated memory CD4+ T 
cells (E) were analyzed. * p<0.05; ** p<0.01; Paired Student’s t test. 
F) Association of NLRP3 expression with the frequency of total leukocytes, CD8+ T 
cells and activated memory CD4+ T cells in patients responding to anti-PD-1 therapy. 
Results show transcriptomics data obtained from tumor biopsies at the on-treatment 
stage.  
See also Tables S1-6. 
 
Figure 5. Analysis of the inflammasome signature in tumor biopsies from 
melanoma patients treated with immune checkpoint blockers (cohort by Chen et al. 
2016)  
A) The log2-transformed normalized NanoString counts from melanoma tumor 
biopsies for the indicated inflammasome-related genes is shown for patients being treated 
with anti-PD-1. The results for responding and non-responding patients as defined by 




Paired analysis of the 16 inflammasome-related genes studied in (A) comparing pre-
treatment and on-treatment tumor biopsies from melanoma patients responding (n= 5) or 
not responding (n= 7) to anti-PD-1 therapy. See color code to identify each gene in Figure 
S7C. * p<0.05; *** p<0.001; **** p<0.0001; Paired Student’s t test.  
See also Figures S6 and S7.  
 
Figure 6. Targeting Tmem176b with Bayk8644 triggers inflammasome-dependent 
antitumor immunity 
A) Identification of Tmem176b inhibitors. CHO-7 cells were transfected with 
Tmem176b and Tmem176a-mCherry-coding pSecTag2B plasmids. Cells were then 
loaded with the Na+-sensitive fluorescent dye Asante NaTRIUM Green 2 (ANG-2). Left 
panels show representative flow cytometry histograms assessing ANG-2 fluorescence in 
the indicated conditions. The right panel shows quantification of ANG-2 mean 
fluorescence intensity (MFI) subtracting in each condition the MFI obtained in Na+-free 
buffer. Untreated and (+) BayK8644-treated cells were studied. One experiment 
representative of five is shown. ** p<0.01; *** p<0.001; Two-way ANOVA test. 
B) Tmem176b-coding mRNA was injected in Xenopus oocytes. Forty-eight h later, 
oocytes were left untreated or activated (treated for 30 min with 0.1 µM PMA and 
extracellular pH 5.0 as previously described (Segovia et al., 2014)). Tmem176b-
dependent conductance was assessed in conditions were 10 µM (+) BayK8644 was 
added to extracellular buffer during PMA stimulation. Representative currents are shown 
in the left panel. Determination of Tmem176b current at 800s post-extracellular 
acidification is depicted in the right graph. *** p<0.001; One-way ANOVA test.  
C) WT and Tmem176b-/- BMDCs were primed for 3 h with LPS and then left untreated 
or treated with 2.5 µM BayK8644. IL-1 was determined in culture supernatants by ELISA. 
One experiment representative of three is shown.  * p<0.05; Two-way ANOVA test. 
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D) LPS-primed WT BMDCs were treated with 10 µM BayK8644 alone or in 
combination with TEA (2 mM) or HCQ (10 µM) to inhibit Ca++-activated K+ channels. IL-1 
was determined in culture supernatants by ELISA. One experiment representative of three 
is shown.  * p<0.05; ** p<0.01; One-way ANOVA test. 
E) The human macrophage cell line (THP-1) was transfected with GFP or 
TMEM176B/GFP-coding plasmids and treated with LPS + nigericine (LPS/Nig) or left 
untreated in the presence of ethanol (vehicle) or 5 µM BayK8644. IL-1 was determined in 
culture supernatants by ELISA. To calculate the extent of TMEM176B-dependent 
inhibition, IL-1 levels (pg/ml) were incorporated to the formula: [GFP/LPS/Nig – GFP 
untreated] – TMEM176B/LPS/Nig x 100. One experiment representative of three is 
shown. * p<0.05; Student’s t test. 
In F, G, H, K, L, M and O the ratio shows the number of surviving mice/ total injected 
mice. For these experiments, we used C57BL/6 mice. 
F) Tmem176b WT and Tmem176b-/- mice were inoculated with EG7 tumor cells and 
treated with 1 mg/kg Bayk8644 i.p on days 2-15 after tumor cell injection. Mice survival 
was monitored. * p<0.05; Log-rank (Mantel-Cox) test.   
G) WT (C57BL/6JN) or Caspase 1/11-/- mice were inoculated with EG7 tumor cells 
and left untreated or treated with BayK8644 as in F. Mice survival was monitored. ** 
p<0.01; Log-rank (Mantel-Cox) test.  
H) WT mice were injected with EG7 tumor cells and left untreated or treated with 
BayK8644 as in G. TDLN were resected 14 days after tumor injection and caspase-1 
activation was studied by flow cytometry using the FLICA1 reagent. * p<0.05; Student’s t 
test. 
I) WT mice were inoculated with EG7 tumor cells and left untreated or treated with 
BayK8644 from days 2-15. At day 15, in vivo cytotoxicity against OVA antigen was 
studied. * p<0.05; Student’s t test. 
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J) WT mice were inoculated with EG7 tumor cells and left untreated or treated with 
BayK8644 or BayK8644 in the absence or presence of anti-CD8 depleting antibody. Mice 
survival was studied. ns: non significant. WT + Vehicle vs WT + BayK8644: * p<0.05; WT 
+ BayK8644 vs WT + BayK8644 + anti-CD8: * p<0.05; WT + Vehicle vs WT + BayK8644 
+ anti-CD8: ns; Log-rank (Mantel-Cox) test. 
K) WT mice were inoculated with EG7 tumor cells and left untreated or treated with 
BayK8644, anti-CTLA-4 antibodies or BayK8644 plus anti-CTLA-4 antibodies. Mice 
survival was monitored. ns: non significant. Untreated vs Bayk8644 + anti-CTLA-4: ** 
p<0.01; BayK8644 vs BayK8644 + anti-CTLA-4: ns; anti-CTLA-4 vs BayK8644 + anti-
CTLA-4: ns; Untreated vs anti-CTLA-4: ns; Untreated vs BayK8644: ns; Log-rank (Mantel-
Cox) test. 
L) WT mice were inoculated with EG7 tumor cells and then treated with 250 µg anti-
PD-1 antibody at days 6, 9 and 12 after tumor inoculation. BayK8644 was injected every 
day since day 9 (all mice had established tumors) until day 21. Mice survival was 
monitored. * p<0.05; Log-rank (Mantel-Cox) test. 
M) OVA-specific CD8+ T cells were assessed using fluorescent MHC pentamers and 
analyzed by flow cytometry in EG7 tumor suspensions from WT mice treated with anti-PD-
1 alone or anti-PD-1 + BayK8644 in a therapeutic protocol as in M. * p<0.05; Unpaired 
Student’s t test. 
N) WT mice were inoculated with EG7 tumor cells and left untreated or treated with 
BayK8644 + anti-PD-1 or BayK8644 + anti-PD-1 + anti-CD8 depleting antibody. Mice 
survival was monitored. * p<0.05; Log-rank (Mantel-Cox) test. 
O) WT mice were inoculated with 5555 melanoma cells and left untreated or treated 
either with anti-PD-1 antibody (days 6, 9 and 12), BayK8644 (days 9-21) or both. All 
animals had established tumors when BayK8644 treatment was started. Mice survival was 
monitored. ns: non significant. Untreated vs Bayk8644 + anti-PD-1: * p<0.05; BayK8644 
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vs BayK8644 + anti-PD-1: ns; PD-1 vs BayK8644 + anti-PD-1: ns; Untreated vs anti-PD-1: 
ns; Untreated vs BayK8644: ns; Log-rank (Mantel-Cox) test. 






















Contact for reagent and resource sharing 
Further information and requests for resources and reagents should be directed to and will 




Six-to-ten weeks old male or female C57BL/6 or BALB/c mice were used (Jackson Lab; 
Bar Harbor, ME) and bred for up to 20 generations at the Institut Pasteur 
Montevideo or at the Institute of Biology and Experimental Medicine, Buenos 
Aires. All experiments were performed according to local regulation and approved by the 
local Ethics Committee for animal experimentation.  
 Tmem176b-/- mice were generated in the 129/SvJ strain and heterozygous mice 
were backcrossed for 10 generations onto the C57BL/6 background (Janvier, Saint 
Berthevin, France) as reported (Segovia et al., 2014). Nlrp3-/- (B6.129S6-Nlrp3 tm1Bhk/J; 
021302) and Caspase1/11 - / - (B6N.129S2-Casp1 tm1Flv/J; 016621) were from The 
Jackson Laboratory. Nlrp3 - / - animals were compared to 000664 C57BL/6J, and 
Caspase1/11 - / -  mice to 005304 C57BL/6NJ. Tmem176b-/-Caspase1-/- mice were 
generated by microinjecting Crispr/Cas9 targeting Caspase-1 in Tmem176b-/- embryos. F1 
animals were genotyped and heterozygous mice were crossed to generate F2 
homozygous Tmem176b-/-Caspase 1-/- animals. Caspase-1 deficiency was confirmed by 
Western blot (Figure S1). All animal strains including Tmem176b-/-, Tmem176b+/+ WT 
(issued from littermate controls), C57BL/6J, Nlrp3-/-, C57BL/JN, Caspase-1/11-/- and 
Tmem176b-/-Caspase1-/- were bred at a specific pathogen-free animal facility (Institut 






EG7 (expressing the OVA antigen), LL2, CT26, THP-1 and CHO-K1 cell lines were 
purchased from ATCC (Manassas, VA). MC38 cells were from Kerafast (Boston, MA). 
The 5555 melanoma cell lines were kindly provided by R. Marais (Cancer Research UK, 
Manchester) and cultured as described (Hirata et al., 2015). 
 
Tumor models and treatments 
C57BL/6 mice were injected s.c. with 1 x 106 MC38 colon cancer cells, 1 x 105 LL2 lung 
cancer cells, 2.5 x 105 5555 melanoma cells or 1 x 106 EG7 thymic lymphoma cells. 
BALB/C animals were injected with 1 x 105 CT26 colon cancer cells. Injection was 
performed alternating one WT and one Tmem176b-/- mouse until completing both groups. 
In treated animals, alternation was done between drug- and vehicle-treated animals. 
Tumor growth was measured manually every 2-3 days with a caliper. The two major 
diameters were taken. Mice were sacrificed when one of the diameters reached 2 cm. In 
experiments where anti-IL-1, anti-IL-17A or control goat IgG were used, 4 µg antibody 
was injected i.p 7 days after inoculation of tumor cells. Injections were repeated every five 
days until day 27 post-injection or euthanasia. For depletion of CD8+ T cells, 100 µg YTS 
169.4 antibody was injected every three days starting from the day before tumor 
inoculation. Depletion was confirmed in the spleen by flow cytometry. For administration of 
anti-CTLA-4 or control IgG, 100 µg antibody was given i.p starting from day 6 after tumor 
inoculation. Injections were repeated every three days until day 12. Anti-PD-1 or control 
IgG was injected (250 µg i.p) starting from day 6 and every three days until day 12.  
Bayk8644 or vehicle control (ethanol) was given i.p at 1 mg/kg since day 3 after tumor 
inoculation and until day 15. In animals treated with BayK8644 and anti-CTLA-4 antibody, 
BayK8644 was injected at days 3-15 every day and anti-CTLA-4 at days 6, 9 and 12 after 
tumor inoculation. In mice treated with BayK8644 and anti-PD-1 antibody, treatment with 
the former started at day 9 and repeated every day until day 21 after tumor inoculation. 
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Anti-PD-1 treatment started at day six after tumor inoculation and repeated every three 
days until day 12.  
 
In vivo inflammasome activation 
C57BL/6 animals were injected with 20 mg/kg ATP i.p. Four hours later, peritoneal lavage 
was performed using 5 ml PBS. Peritoneal cells were centrifuged and then stained with 
anti-CD11b, anti-Ly6C and anti-Ly6G antibodies. Cells were analyzed by flow cytometry. 
The percentage of Ly6Cint Ly6Ghi cells within the CD11b+ cell compartment (neutrophils) 
was determined. The absolute number of neutrophils was calculated for each condition.  
 
In vitro inflammasome activation 
Bone marrow-derived DCs (BMDCs) were differentiated by culturing bone marrow cells for 
8 days in the presence of 0.4 ng/ml GM-CSF. At day 8, adherent cells were >95% 
CD11c+CD11b+MHC class IIint. Cells were stimulated for 3 h with 0.25 µg/ml LPS, washed 
and treated with the indicated doses of ATP or nigericin. The presence of IL-1 was 
assessed in culture supernatants by ELISA (Biolegend, 432603) . To determine caspase-
1 activation, BMDCs were stained with FLICA1 45 min after ATP or nigericin stimulation 
and analyzed by flow cytometry. For Western blot experiments, culture supernatants from 
BMDCs stimulated in the absence of FBS were precipitated with 20 % (v/v) TCA and 
washed with acetone. Cell lysates were generated with RIPA buffer in the presence of a 
protease inhibitor cocktail. Cell lysates and precipitates from culture supernatants were 
electrophoresed, blotted and probed with anti-caspase-1 (Adipogen, AG-20B-0042) or 
anti-IL-1 (Santa Cruz Biotechnol, sc-7884) antibodies. 
  
THP-1 transfection and inflammasome activation 
THP-1 monocytes were differentiated into macrophages by treatment with 0.1 µM PMA for 
48 h. Macrophages (2.5 x 106) were then detached using trypsine and nucleofected with 
the GFP or GFP-TMEM176B coding pcDNA1.3 plasmids using the Amaxa Cell Line 
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Nucleofector Kit V-Lonza and nucleofector device from Amaxa. Sixteen hours later, cells 
were treated for 3 h with 0.25 µg/ml LPS. Cells were washed and treated for 2 h with 2.5 
µM nigericin. IL-1 was assessed by ELISA in culture supernatants.  
 
Method details 
Cytosolic Ca++ determination 
BMDCs cultured on glass coverslips were loaded with 1 µM Fura-2 for 45 min in the dark. 
Cells were then washed and analyzed by time-lapse microscopy at 37°C. Fluorescence 
emission intensity at 510 nm was determined in individual wells alternating excitation 
wavelengths of 340 and 380 nm every 3 sec. ATP was added when indicated at 0.5 mM.  
 
In vivo cytotoxicity assay 
Splenocytes from naïve C57BL/6 mice were stained alternatively with 0.8 (high) or 0.08 
µM (low) DDAO-SE probe. The high DDAO population was loaded for 60 min at 37°C with 
50 µM SIINFEKL OVA peptide. After three washes, the high and low population were 
mixed at 1:1 ratio. The mixed cells (2 x 106) were injected i.v in WT, Tmem176b-/- or 
Tmem176b-/-Caspase1-/- naïve and tumor-bearing mice. Four hours later, mice were 
sacrificed and the spleens harvested. Splenocytes were analyzed by flow cytometry to 
assess DDAO high and low populations. Specific cytotoxicity was calculated with the 
following formula: 
% specific lysis= (1-[rnaïve/rtumor bearing])x100 
 
r = %DDAOlow cells/%DDAOhigh cells 
 
 
Screening of Tmem176b inhibitors 
CHO cells were transfected using Lipofectamine2000 with pSecTag2B-PS-Tmem176a-
mCherry and pSecTag2B-PS-Tmem176b-V5His plasmids for 4 h, washed and cultured for 
24 h. Cells were then loaded with 1 µM ANG-2 for 30 min at 37°C, washed and incubated 
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in 140 mM Na+-containing phosphate buffer or 140 mM NMDG to substitute Na+ in the 
presence of different doses of tested drugs or vehicle controls.  Cells were then analyzed 
by flow cytometry using a BD Accuri C6 cytometer equipped with a 488 nm laser.  ANG-2 
emission was detected using band-pass filter 670 LP. FlowJo vX.0.7 software was used 
for data analysis. MFI from NMDG-containing solutions was subtracted to MFI from Na+-
containing solutions. A maximum of two drugs was studied in each experiment. Screened 
drugs were from SCREEN-WELL® Ion Channel ligand library (Enzo Life Sciences; 
Farmingdale, NY). 
 
Immunohistochemistry staining of human colon microarrays 
Expression of TMEM176B was analyzed by immunohistochemistry on 90 specimens of 
human colon tumors (US Biomax, Inc; Rockville, MD). Briefly, antigenic recovery was 
done by boiling slides in a pressure cooker for 10 min in the presence of alkaline buffer 
(10 mM Tris, 1 mM EDTA, 0.05% Tween 20, pH 9.0). 2.5 g/ml anti-TMEM176B antibody 
(Abcam; ab103929) or control rabbit IgG were incubated ON at 4ºC. Staining was verified 
using EnVision+ System- HRP-labelled polymer anti-rabbit (Dako/Agilent, Santa Clara 
CA). Slides were counterstained with Meyer´s hematoxylin, analyzed by two independent 
researchers in a blind fashion and categorized as high or low/negative TMEM176B 
expression in the stroma and parenchyma. Expression levels were then correlated with 
survival information provided by US Biomax.  
 
Electrophysiology experiments 
Oocytes were surgically removed from MS222 (0.4%)‐anesthetized Xenopus 
laevis female and dissociated under gentle agitation by a 2–3 h incubation in an OR2 
solution (82 mM NaCl; 2 mM KCl; 1 mM MgCl2; 5 mM HEPES pH 7.2) supplemented with 
collagenase 1A (1 mg/ml). Oocytes were then injected with 40 nl of in 
vitro synthesized Tmem176b mRNA at 1 µg/µL (mMESSAGE mMACHINE Ultra 
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kit). Tmem176b was fused to a signal peptide sequence (N‐terminal) from pSecTag2B 
(Invitrogen, Carlsbad, CA) and to V5 + 6‐His tags (C‐terminal). The day after injection, 
oocytes were placed in a pH 8.0 solution (100 mM NaCl, 3 mM KCl, 2 mM MgCl2, 15 mM 
HEPES pH 8.0) changed daily. Two to three days later, currents were recorded in 
two‐electrode voltage‐clamp using a genclamp500 amplifier (Axon Inst., Foster City, CA) 
interfaced to a personal computer using the Digidata 1200 interface and the pClamp 
software (v 7.0; Axon Inst.). Prior to recording, oocytes were incubated in PMA at 0.1 µM 
in pH 8.0 solution for 20–30 min. Currents were filtered at 100 Hz and digitalized at 0.5 
 kHz before storage and further analysis. During recording, oocytes were continuously 
superfused with the pH 8.0 solution. The currents were quantified 5–15 min after holding 
the extracellular pH at 5.0. In Tmem176b-expressing oocytes, induction of an inward 
current was obtained by switching to a pH 5.0 solution.  
 
Gene expression analysis 
Normalized NanoString nCounter data were analyzed from Chen et al (2016). Gene 
expression data from Riaz et al (2017) were obtained from their GitHub repository 
(https://github.com/riazn/bms038_analysis/tree/master/data). RNA-seq count data were 
normalized to FPKM (Fragment per kilobase per million) through the Bioconductor R 
package DESeq2 1.18.1. The on-treatment biopsy from patient 32 was excluded from 
further analyses since it presented extreme expression values. 
 
CIBERSORT analysis 
The leukocyte signature matrix LM22 (547 genes) that discriminates 22 types of tumor-
infiltrating immune cells was used for analysis. Normalized gene expression data from 
Riaz et al. (2017) cohort were processed with the CIBERSORT web tool 
(http://cibersort.stanford.edu/) setting no quantile normalization and 1.000 permutations as 
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parameters. All samples were run with both relative and absolute modes. The first mode 
infers the relative cellular fraction for each cell of the LM22 matrix and the second 
calculates a score that reflects the absolute proportion of each cell type in the mixture. 
 
Single cell RNA-Seq data analysis 
Normalized single cell expression data from Jerby-Arnon et al. (2018) was obtained from 
Gene Expression Omnibus (Accession number GSE115978). To study gene correlations, 
the expression matrix was processed with the software MAGIC (van Dijk et al., 2018) to 
deal with the under-sampling of mRNA known as dropouts. R implementation of the 
MAGIC algorithm with default parameters (Rmagic v1.3.0) was applied. For correlation 
analysis, Spearman's Rank Correlation test was used. 
 
Statistical analyses 
Statistical analyses were performed either by R project or GraphPad Prism 6 (GraphPad 
Software, Inc., La Jolla, CA). Survival analyses were done with the Log-rank (Mantel-Cox) 
test. Comparison of two experimental conditions was done with paired or unpaired 
Student’s t test. Comparison of multiple conditions was done with one or two-way ANOVA 
tests. Differences in gene expression and CIBERSORT scores between responder and 
non-responder groups were assessed using the unpaired t-test when normality 
assumption was met. Otherwise, Mann-Whitney U test was used. Differences between 
matched samples pre- and on-treatment were evaluated with paired t-test when normality 
assumption was met or otherwise with Wilcoxon signed-rank test. For correlation analysis, 
the Pearson coefficient was used when samples passed the normality test. Spearman 
coefficient was used for all other cases. Shapiro-Wilk test was performed to evaluate the 
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